Smith & Nephew (LON:SN) Stock Price Target Lowered at Jefferies Financial Group

Smith & Nephew (LON:SN) had its price target cut by stock analysts at Jefferies Financial Group from GBX 1,500 to GBX 1,400 in a research report issued to clients and investors on Thursday, London Stock Exchange reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group‘s target price points to a potential upside of 17.65% from the stock’s current price.

Several other research firms have also commented on SN. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,250 target price on shares of Smith & Nephew in a report on Tuesday, September 15th. Citigroup cut shares of Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. Berenberg Bank lowered their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of GBX 1,242.50.

Smith & Nephew Stock Performance

LON SN opened at GBX 1,190 on Thursday. The stock has a market cap of £13.05 billion, a price-to-earnings ratio of 42.84, a P/E/G ratio of 0.46 and a beta of 0.69. The company’s fifty day moving average is GBX 1,053.81 and its 200-day moving average is GBX 1,152.03. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.